TECP
CMPX icon

Trails Edge Capital Partners’s Compass Therapeutics CMPX Stock Holding History

Trails Edge Capital Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,415,273
Closed -$7.6M – 30
2025
Q4 		$7.6M Buy
+1,415,273
New +$6.54M 1.88% 20

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trails Edge Capital Partners's CMPX Position: Q1 2026 in Review

Trails Edge Capital Partners sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 1,415,273 shares — an estimated $7.6M sold.

Trails Edge Capital Partners first reported a position in CMPX in Q4 2025 and held it in 1 quarter. The position peaked at $7.6M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Trails Edge Capital Partners reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Trails Edge Capital Partners sold 1,415,273 Compass Therapeutics shares in Q1 2026, an estimated $7.6M.
  • Trails Edge Capital Partners first reported a position in Compass Therapeutics in Q4 2025 and held it in 1 quarter.
  • Trails Edge Capital Partners's Compass Therapeutics position peaked at $7.6M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.